| Biomarker ID | 1527 |
| PMID | 25174820 |
| Year | 2014 |
| Biomarker | Yin Yang 1 (YY1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: SREBP signaling, PRC2 complex long-term gene silencing through modification of histone tails, HES/HEY pathway, Signaling events mediated by HDAC class I, E2F transcription factor network |
| Experiment | High Grade cancer Vs Low grade Cancer |
| Type of Biomarker | Prognostic |
| Cohort | The 54 cases of PCa were classified according to the Gleason score as follows: 27 lowâ€grade prostatic carcinoma [Gleason score 2â€5 (LG PCa)] and 27 highâ€grade prostatic carcinoma [Gleason score 6â€10 (HG PCa)] |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | P<0.0001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |